	US 11,883,416 B2
	Methods and compositions for the treatment of IL13Ra2—overexpressing cancer
José Ignacio Casal Álvarez, Madrid (ES); and Rubén Álvaro Bartolomé Conde, Madrid (ES)
Assigned to CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC), Madrid (ES)
Filed by CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC), Madrid (ES)
Filed on Dec. 3, 2021, as Appl. No. 17/541,924.
Claims priority of provisional application 63/121,790, filed on Dec. 4, 2020.
Prior Publication US 2022/0233552 A1, Jul. 28, 2022
Int. Cl. A61P 35/00 (2006.01); A61K 31/575 (2006.01)

CPC A61K 31/575 (2013.01) [A61P 35/00 (2018.01)]

2 Claims

1. A method of treatment of IL13Rα2-overexpressing cancer in a subject, wherein the treatment comprises administering to said subject an effective amount of a protein tyrosine phosphatase-1B (PTP1B) inhibitor, wherein the PTP1B inhibitor is Claramine, and wherein the cancer is glioblastoma (GBM), metastatic colorectal cancer (CRC), or ovarian cancer (OC).